

Health2Sync inks MoU with AstraZeneca Taiwan for chronic kidney disease management

14 July 2022 | News

In Taiwan, Acute and Chronic Kidney Disease is reported to cost almost \$1.8 billion every year, making it the costliest disease to the National Health Insurance system



Taiwan-based startup Health2Sync is signing a Memorandum of Understanding (MoU) with AstraZeneca Taiwan to provide its first digital solution for chronic kidney disease (CKD) patients in Taiwan.

The partnership targets to reach an early diagnosis and optimize the quality of everyday chronic kidney disease care through the smart detection feature on the Health2Sync patient management platform, which is currently used by over 400 medical institutions worldwide.

Aligned with AstraZeneca's ambition to increase earlier CKD diagnosis and help slow disease progression, the latest version of the Health2Sync Patient Management Platform will automatically filter and categorize patients into various groups according to their lab results, and notify the healthcare professionals as well as patients for early intervention, which may prevent disease progression and reduce the risk of complications.

Once the Platform identifies patients' CKD risk levels, physicians can review the analysis and the long-term trends of the examination data, and align it with medical interventions. Patients can also utilize the easy-to-use mobile app to consult their care providers for timely adjustments of medication regimens, enabling better chronic disease care.